Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Non-Small Cell Lung Carcinoma Patients: the ROSING Study.

Conde E, Hernandez S, Martinez R, Angulo B, De Castro J, Collazo-Lorduy A, Jimenez B, Muriel A, Mate JL, Moran T, Aranda I, Massuti B, Rojo F, Domine M, Sansano I, Garcia F, Felip E, Mancheño N, Juan O, Sanz J, Gonzalez-Larriba JL, Atienza-Cuevas L, Arriola-Arellano E, Abdulkader I, Garcia-Gonzalez J, Camacho C, Rodriguez-Abreu D, Teixido C, Reguart N, Gonzalez-Piñeiro A, Lazaro-Quintela M, Lozano MD, Gurpide A, Gomez-Roman J, Lopez-Brea M, Pijuan L, Salido M, Arriola E, Company A, Insa A, Esteban-Rodriguez I, Saiz M, Azkona E, Alvarez R, Artal A, Plaza ML, Aguiar D, Enguita AB, Benito A, Paz-Ares L, Garrido P, Lopez-Rios F.

J Thorac Oncol. 2019 Jul 23. pii: S1556-0864(19)30562-3. doi: 10.1016/j.jtho.2019.07.005. [Epub ahead of print]

2.

Programmed death-ligand 1 expression on direct Pap-stained cytology smears from non-small cell lung cancer: Comparison with cell blocks and surgical resection specimens.

Lozano MD, Abengozar-Muela M, Echeveste JI, Subtil JC, Bertó J, Gúrpide A, Calvo A, de Andrea CE.

Cancer Cytopathol. 2019 Jul;127(7):470-480. doi: 10.1002/cncy.22155. Epub 2019 Jun 27.

PMID:
31245924
3.

Clinical Management of Cutaneous Adverse Events in Patients on Chemotherapy: A National Consensus Statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology.

Sanmartín O, Beato C, Suh-Oh HJ, Aragón I, España A, Majem M, Segura S, Gúrpide A, Botella R, Grávalos C.

Actas Dermosifiliogr. 2019 Jul - Aug;110(6):448-459. doi: 10.1016/j.ad.2019.01.011. Epub 2019 Apr 19. English, Spanish.

PMID:
31010573
4.

Identification of mutations associated with acquired resistance to sunitinib in renal cell cancer.

Elgendy M, Fusco JP, Segura V, Lozano MD, Minucci S, Echeveste JI, Gurpide A, Andueza M, Melero I, Sanmamed MF, Ruiz MR, Calvo A, Pascual JI, Velis JM, Miñana B, Valle RD, Pio R, Agorreta J, Abengozar M, Colecchia M, Brich S, Renne SL, Guruceaga E, Patiño-García A, Perez-Gracia JL.

Int J Cancer. 2019 Oct 1;145(7):1991-2001. doi: 10.1002/ijc.32256. Epub 2019 Mar 30.

PMID:
30848481
5.

The Dynamic Use of EGFR Mutation Analysis in Cell-Free DNA as a Follow-Up Biomarker during Different Treatment Lines in Non-Small-Cell Lung Cancer Patients.

Macías M, Alegre E, Alkorta-Aranburu G, Patiño-García A, Mateos B, Andueza MP, Gúrpide A, Lopez-Picazo JM, Gil-Bazo I, Perez-Gracia JL, González Á.

Dis Markers. 2019 Jan 23;2019:7954921. doi: 10.1155/2019/7954921. eCollection 2019.

6.

Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma.

Schalper KA, Rodriguez-Ruiz ME, Diez-Valle R, López-Janeiro A, Porciuncula A, Idoate MA, Inogés S, de Andrea C, López-Diaz de Cerio A, Tejada S, Berraondo P, Villarroel-Espindola F, Choi J, Gúrpide A, Giraldez M, Goicoechea I, Gallego Perez-Larraya J, Sanmamed MF, Perez-Gracia JL, Melero I.

Nat Med. 2019 Mar;25(3):470-476. doi: 10.1038/s41591-018-0339-5. Epub 2019 Feb 11.

PMID:
30742120
7.

Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology.

Grávalos C, Sanmartín O, Gúrpide A, España A, Majem M, Suh Oh HJ, Aragón I, Segura S, Beato C, Botella R.

Clin Transl Oncol. 2019 May;21(5):556-571. doi: 10.1007/s12094-018-1953-x. Epub 2018 Oct 3.

PMID:
30284232
8.

Genomic characterization of individuals presenting extreme phenotypes of high and low risk to develop tobacco-induced lung cancer.

Fusco JP, Pita G, Pajares MJ, Andueza MP, Patiño-García A, de-Torres JP, Gurpide A, Zulueta J, Alonso R, Alvarez N, Pio R, Melero I, Sanmamed MF, Rodriguez Ruiz M, Gil-Bazo I, Lopez-Picazo JM, Casanova C, Baz Davila R, Agudo A, Lozano MD, Gonzalez A, Sala N, Ardanaz E, Benitez J, Montuenga L, Gonzalez-Neira A, Perez-Gracia JL.

Cancer Med. 2018 May 15. doi: 10.1002/cam4.1500. [Epub ahead of print]

9.

[The role of chemotherapy in the treatment of hormone sensitive metastatic prostate cancer.]

Pérez-Gracia JL, Diez Caballero F, Gúrpide A, de Fata Chillón FR, Villacampa F.

Arch Esp Urol. 2018 Mar;71(3):276-280. Review. Spanish.

PMID:
29633948
10.

Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients.

Rodríguez-Ruiz ME, Perez-Gracia JL, Rodríguez I, Alfaro C, Oñate C, Pérez G, Gil-Bazo I, Benito A, Inogés S, López-Diaz de Cerio A, Ponz-Sarvise M, Resano L, Berraondo P, Barbés B, Martin-Algarra S, Gúrpide A, Sanmamed MF, de Andrea C, Salazar AM, Melero I.

Ann Oncol. 2018 May 1;29(5):1312-1319. doi: 10.1093/annonc/mdy089.

PMID:
29554212
11.

Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients.

Sanmamed MF, Perez-Gracia JL, Schalper KA, Fusco JP, Gonzalez A, Rodriguez-Ruiz ME, Oñate C, Perez G, Alfaro C, Martín-Algarra S, Andueza MP, Gurpide A, Morgado M, Wang J, Bacchiocchi A, Halaban R, Kluger H, Chen L, Sznol M, Melero I.

Ann Oncol. 2017 Aug 1;28(8):1988-1995. doi: 10.1093/annonc/mdx190.

12.

Strategies to design clinical studies to identify predictive biomarkers in cancer research.

Perez-Gracia JL, Sanmamed MF, Bosch A, Patiño-Garcia A, Schalper KA, Segura V, Bellmunt J, Tabernero J, Sweeney CJ, Choueiri TK, Martín M, Fusco JP, Rodriguez-Ruiz ME, Calvo A, Prior C, Paz-Ares L, Pio R, Gonzalez-Billalabeitia E, Gonzalez Hernandez A, Páez D, Piulats JM, Gurpide A, Andueza M, de Velasco G, Pazo R, Grande E, Nicolas P, Abad-Santos F, Garcia-Donas J, Castellano D, Pajares MJ, Suarez C, Colomer R, Montuenga LM, Melero I.

Cancer Treat Rev. 2017 Feb;53:79-97. doi: 10.1016/j.ctrv.2016.12.005. Epub 2016 Dec 30. Review.

13.

SEOM Clinical Guideline update for the prevention of chemotherapy-induced nausea and vomiting (2016).

de Las Peñas R, Blasco A, De Castro J, Escobar Y, García-Campelo R, Gúrpide A, Lopez-Lopez R, Majem M, Rodríguez CA, Virizuela JA.

Clin Transl Oncol. 2016 Dec;18(12):1237-1242. doi: 10.1007/s12094-016-1583-0. Epub 2016 Nov 28.

14.

Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value.

Alegre E, Fusco JP, Restituto P, Salas-Benito D, Rodríguez-Ruiz ME, Andueza MP, Pajares MJ, Patiño-García A, Pio R, Lozano MD, Gúrpide A, Lopez-Picazo JM, Gil-Bazo I, Perez-Gracia JL, Gonzalez A.

Tumour Biol. 2016 Oct;37(10):13687-13694. Epub 2016 Jul 29.

PMID:
27473086
15.

Hypoxia-induced soluble CD137 in malignant cells blocks CD137L-costimulation as an immune escape mechanism.

Labiano S, Palazón A, Bolaños E, Azpilikueta A, Sánchez-Paulete AR, Morales-Kastresana A, Quetglas JI, Perez-Gracia JL, Gúrpide A, Rodriguez-Ruiz M, Aznar MA, Jure-Kunkel M, Berraondo P, Melero I.

Oncoimmunology. 2015 Jun 24;5(1):e1062967. eCollection 2016.

16.

[Treatment of prostate cancer according to life expectancy, comorbidity and clinical practice guidelines].

Pérez-Gracia JL, Rodríguez Ruiz ME, Fusco JP, Gúrpide A.

An Sist Sanit Navar. 2015 Sep-Dec;38(3):463-4. Spanish. No abstract available.

17.

Combined clinical and genomic signatures for the prognosis of early stage non-small cell lung cancer based on gene copy number alterations.

Aramburu A, Zudaire I, Pajares MJ, Agorreta J, Orta A, Lozano MD, Gúrpide A, Gómez-Román J, Martinez-Climent JA, Jassem J, Skrzypski M, Suraokar M, Behrens C, Wistuba II, Pio R, Rubio A, Montuenga LM.

BMC Genomics. 2015 Oct 6;16:752. doi: 10.1186/s12864-015-1935-0.

18.

Assessment of EGFR and KRAS mutation status from FNAs and core-needle biopsies of non-small cell lung cancer.

Lozano MD, Labiano T, Echeveste J, Gurpide A, Martín-Algarra S, Zhang G, Sharma A, Palma JF.

Cancer Cytopathol. 2015 Apr;123(4):230-6. doi: 10.1002/cncy.21513. Epub 2014 Dec 19.

19.

Role of [¹⁸F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer.

Caicedo C, Garcia-Velloso MJ, Lozano MD, Labiano T, Vigil Diaz C, Lopez-Picazo JM, Gurpide A, Zulueta JJ, Richter Echevarria JA, Perez Gracia JL.

Eur J Nucl Med Mol Imaging. 2014 Nov;41(11):2058-65. doi: 10.1007/s00259-014-2833-4. Epub 2014 Jul 3. Erratum in: Eur J Nucl Med Mol Imaging. 2014 Nov;41(11):2164. Zulueta, Javier [corrected to Zulueta, Javier J].

PMID:
24990403
20.

Variations in molecular profile in NSCLC can be analyzed using cytological samples: development of EGFR resistance mutations and coexistence of ALK-EML4 translocation in an EGFR-sensitive patient.

Lozano MD, Labiano T, Zudaire I, Subtil JC, Gúrpide A, Echeveste JI, Zulueta JJ, Martín-Algarra S, Pérez-Gracia JL.

Int J Surg Pathol. 2015 Apr;23(2):111-5. doi: 10.1177/1066896914539551. Epub 2014 Jun 17.

PMID:
24942894
21.

Randomized pharmacokinetic study comparing subcutaneous and intravenous palonosetron in cancer patients treated with platinum based chemotherapy.

Sadaba B, del Barrio A, Campanero MA, Azanza JR, Gomez-Guiu A, Lopez-Picazo JM, Algarra SM, Guillén Grimá F, Blanco Prieto M, Perez-Gracia JL, Gurpide A.

PLoS One. 2014 Feb 27;9(2):e89747. doi: 10.1371/journal.pone.0089747. eCollection 2014.

22.

Adjuvant therapy with bemiparin in patients with limited-stage small cell lung cancer: results from the ABEL study.

Lecumberri R, López Vivanco G, Font A, González Billalabeitia E, Gúrpide A, Gómez Codina J, Isla D, Galán A, Bover I, Domine M, Vicente V, Rosell R, Rocha E.

Thromb Res. 2013;132(6):666-70. doi: 10.1016/j.thromres.2013.09.026. Epub 2013 Sep 27.

PMID:
24491267
23.

Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma.

Prior C, Perez-Gracia JL, Garcia-Donas J, Rodriguez-Antona C, Guruceaga E, Esteban E, Suarez C, Castellano D, del Alba AG, Lozano MD, Carles J, Climent MA, Arranz JA, Gallardo E, Puente J, Bellmunt J, Gurpide A, Lopez-Picazo JM, Hernandez AG, Mellado B, Martínez E, Moreno F, Font A, Calvo A.

PLoS One. 2014 Jan 24;9(1):e86263. doi: 10.1371/journal.pone.0086263. eCollection 2014.

24.

Antitumor immunotherapeutic and toxic properties of an HDL-conjugated chimeric IL-15 fusion protein.

Ochoa MC, Fioravanti J, Rodriguez I, Hervas-Stubbs S, Azpilikueta A, Mazzolini G, Gúrpide A, Prieto J, Pardo J, Berraondo P, Melero I.

Cancer Res. 2013 Jan 1;73(1):139-49. doi: 10.1158/0008-5472.CAN-12-2660. Epub 2012 Nov 13.

25.

The multimodal management of locally advanced N2 non-small cell lung cancer: is there a role for surgical resection? A single institution's experience.

Bosch-Barrera J, García-Franco C, Guillén-Grima F, Moreno-Jiménez M, López-Picazo JM, Gúrpide A, Pérez-Gracia JL, Aristu J, Torre W, García-Foncillas J, Gil-Bazo I.

Clin Transl Oncol. 2012 Nov;14(11):835-41. doi: 10.1007/s12094-012-0874-3. Epub 2012 Jul 20.

PMID:
22855163
26.

Tumor-stromal interactions of the bone microenvironment: in vitro findings and potential in vivo relevance in metastatic lung cancer models.

Luis-Ravelo D, Antón I, Vicent S, Hernández I, Valencia K, Zandueta C, Martínez-Canarias S, Gúrpide A, Lecanda F.

Clin Exp Metastasis. 2011 Dec;28(8):779-91. doi: 10.1007/s10585-011-9409-5. Epub 2011 Jul 28.

PMID:
21796372
27.

Assessment of epidermal growth factor receptor and K-ras mutation status in cytological stained smears of non-small cell lung cancer patients: correlation with clinical outcomes.

Lozano MD, Zulueta JJ, Echeveste JI, Gúrpide A, Seijo LM, Martín-Algarra S, Del Barrio A, Pio R, Idoate MA, Labiano T, Perez-Gracia JL.

Oncologist. 2011;16(6):877-85. doi: 10.1634/theoncologist.2010-0155. Epub 2011 May 14.

28.

Carcinoma-derived interleukin-8 disorients dendritic cell migration without impairing T-cell stimulation.

Alfaro C, Suárez N, Martínez-Forero I, Palazón A, Rouzaut A, Solano S, Feijoo E, Gúrpide A, Bolaños E, Erro L, Dubrot J, Hervás-Stubbs S, Gonzalez A, Perez-Gracia JL, Melero I.

PLoS One. 2011 Mar 14;6(3):e17922. doi: 10.1371/journal.pone.0017922.

29.

Clinical development of combination strategies in immunotherapy: are we ready for more than one investigational product in an early clinical trial?

Perez-Gracia JL, Berraondo P, Martinez-Forero I, Alfaro C, Suarez N, Gurpide A, Sangro B, Hervas-Stubbs S, Ochoa C, Melero JA, Melero I.

Immunotherapy. 2009 Sep;1(5):845-53. doi: 10.2217/imt.09.51. Review.

PMID:
20636027
30.

Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation.

Porta R, Sánchez-Torres JM, Paz-Ares L, Massutí B, Reguart N, Mayo C, Lianes P, Queralt C, Guillem V, Salinas P, Catot S, Isla D, Pradas A, Gúrpide A, de Castro J, Polo E, Puig T, Tarón M, Colomer R, Rosell R.

Eur Respir J. 2011 Mar;37(3):624-31. doi: 10.1183/09031936.00195609. Epub 2010 Jul 1.

31.

Complement activation mediates cetuximab inhibition of non-small cell lung cancer tumor growth in vivo.

Hsu YF, Ajona D, Corrales L, Lopez-Picazo JM, Gurpide A, Montuenga LM, Pio R.

Mol Cancer. 2010 Jun 7;9:139. doi: 10.1186/1476-4598-9-139.

32.

Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancer.

Altorki N, Lane ME, Bauer T, Lee PC, Guarino MJ, Pass H, Felip E, Peylan-Ramu N, Gurpide A, Grannis FW, Mitchell JD, Tachdjian S, Swann RS, Huff A, Roychowdhury DF, Reeves A, Ottesen LH, Yankelevitz DF.

J Clin Oncol. 2010 Jul 1;28(19):3131-7. doi: 10.1200/JCO.2009.23.9749. Epub 2010 Jun 1.

PMID:
20516450
33.

Selection of extreme phenotypes: the role of clinical observation in translational research.

Pérez-Gracia JL, Gúrpide A, Ruiz-Ilundain MG, Alfaro Alegría C, Colomer R, García-Foncillas J, Melero Bermejo I.

Clin Transl Oncol. 2010 Mar;12(3):174-80. Review.

34.

Identification of TNF-alpha and MMP-9 as potential baseline predictive serum markers of sunitinib activity in patients with renal cell carcinoma using a human cytokine array.

Perez-Gracia JL, Prior C, Guillén-Grima F, Segura V, Gonzalez A, Panizo A, Melero I, Grande-Pulido E, Gurpide A, Gil-Bazo I, Calvo A.

Br J Cancer. 2009 Dec 1;101(11):1876-83. doi: 10.1038/sj.bjc.6605409. Epub 2009 Nov 10.

35.

Role of surgery in a multidisciplinary approach to superior sulcus tumors (SST): morbidity and prognostic factors for long-term success after resection.

Torre W, Garcia-Franco C, Tamura A, Gurpide A, Lopez-Picazo J, Aristu J, Moreno M, Pardo J.

Thorac Cardiovasc Surg. 2009 Sep;57(6):353-7. doi: 10.1055/s-0029-1185786. Epub 2009 Aug 25.

PMID:
19707978
36.

Large cell carcinoma of the lung: an endangered species?

Pardo J, Martinez-Peñuela AM, Sola JJ, Panizo A, Gúrpide A, Martinez-Peñuela JM, Lozano MD.

Appl Immunohistochem Mol Morphol. 2009 Oct;17(5):383-92. doi: 10.1097/PAI.0b013e31819bfd59.

PMID:
19444077
37.

Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes.

Alfaro C, Suarez N, Gonzalez A, Solano S, Erro L, Dubrot J, Palazon A, Hervas-Stubbs S, Gurpide A, Lopez-Picazo JM, Grande-Pulido E, Melero I, Perez-Gracia JL.

Br J Cancer. 2009 Apr 7;100(7):1111-9. doi: 10.1038/sj.bjc.6604965. Epub 2009 Mar 10.

38.

Dosimetric analysis of the patterns of local failure observed in patients with locally advanced non-small cell lung cancer treated with neoadjuvant chemotherapy and concurrent conformal (3D-CRT) chemoradiation.

Moreno-Jiménez M, Aristu J, López-Picazo JM, Ramos LI, Gúrpide A, Gómez-Iturriaga A, Valero J, Martínez-Monge R.

Radiother Oncol. 2008 Sep;88(3):342-50. doi: 10.1016/j.radonc.2008.05.019. Epub 2008 Jun 14.

PMID:
18558448
39.

[New treatments for renal carcinoma].

Pérez-Gracia JL, López-Picazo JM, Olier C, Alfaro C, García-Foncillas J, Melero I, Gúrpide A.

An Sist Sanit Navar. 2007 Sep-Dec;30(3):393-403. Review. Spanish.

40.

Randomized crossover pharmacokinetic evaluation of subcutaneous versus intravenous granisetron in cancer patients treated with platinum-based chemotherapy.

Gurpide A, Sadaba B, Martin-Algarra S, Azanza JR, Lopez-Picazo JM, Campanero MA, Cabello JP, Gil-Aldea I, de la Cruz S, Fernandez Gallego V, Reyna C, Olier Garate C, Blanco-Prieto MJ, Ceballos J, Garcia-Foncillas J, Perez-Gracia JL.

Oncologist. 2007 Sep;12(9):1151-5.

41.

[Small-cell lung cancer].

Pérez-Gracia JL, López-Picazo JM, Martín-Algarra S, Viteri S, García-Foncillas J, Gúrpide A.

Rev Med Univ Navarra. 2007 Apr-Jun;51(2):7-13. Review. Spanish.

PMID:
17886708
42.

Total remission of thymus carcinoma after treatment with intravenous immunoglobulin.

Murie-Fernández M, Gurpide A, de la Cruz S, de Castro P.

Clin Transl Oncol. 2006 Sep;8(9):697-9.

PMID:
17005475
43.

[Bone metastases].

Vicent S, Luis-Ravelo D, Antón I, Hernández I, Martínez S, de las Rivas J, Gúrpide A, Lecanda F.

An Sist Sanit Navar. 2006 May-Aug;29(2):177-88. Spanish.

44.

[Medium and long-term results of the use of videothorascopy in surgery of pulmonary metastasis resection].

Torre W, Rodríguez-Spiteri N, Villalobos W, Gurpide A, Fernández O, López-Picazo JM.

An Sist Sanit Navar. 2005;28 Suppl 3:93-102. Spanish.

45.

Activity of gefitinib in central nervous system metastases in patients with non-small-cell lung cancer: two case reports and a review of the literature.

Gurpide A, Perez-Gracia JL, Lopez-Picazo JM, Moreno M, Zubieta JL, Martin-Algarra S, Garcia-Foncillas J.

Clin Lung Cancer. 2005 Sep;7(2):138-40. Review.

PMID:
16179102
46.

Assessment of the value of confirming responses in clinical trials in oncology.

Perez-Gracia JL, Muñoz M, Williams G, Wu J, Carrasco E, Garcia-Ribas I, Peiro A, Lopez-Picazo JM, Gurpide A, Chopitea A, Martín-Algarra S, García-Foncillas J, Blatter J.

Eur J Cancer. 2005 Jul;41(11):1528-32.

PMID:
16026690
47.

Paclitaxel, cisplatin, and vinorelbine combination chemotherapy in metastatic non-small-cell lung cancer.

Cortes J, Rodriguez J, Calvo E, Gurpide A, Garcia-Foncillas J, Salgado E, Aramendia JM, Lopez-Picazo JM, Hernandez B, Hidalgo R, Aristu JJ, Brugarolas A, Martin-Algarra S.

Am J Clin Oncol. 2004 Jun;27(3):299-303.

PMID:
15170152
48.

Front-line paclitaxel/cisplatin-based chemotherapy in brain metastases from non-small-cell lung cancer.

Cortes J, Rodriguez J, Aramendia JM, Salgado E, Gurpide A, Garcia-Foncillas J, Aristu JJ, Claver A, Bosch A, Lopez-Picazo JM, Martin-Algarra S, Brugarolas A, Calvo E.

Oncology. 2003;64(1):28-35.

PMID:
12457029
49.

Comparison of unidimensional and bidimensional measurements in metastatic non-small cell lung cancer.

Cortes J, Rodriguez J, Diaz-Gonzalez JA, Garzon C, Gurpide A, Arbea L, Gil-Bazo I, Navarro V, Cambeiro M, Nicolas AI, Martin-Algarra S, Garcia-Foncillas J, Calvo E.

Br J Cancer. 2002 Jul 15;87(2):158-60.

50.

[Spontaneous tumor regression in a patient with multiple myeloma. Report of another case].

García-Rayo S, Gúrpide A, Vega F, Brugarolas A.

Rev Med Univ Navarra. 1996 Jul-Sep;40(3):41-2. Spanish.

PMID:
9499825

Supplemental Content

Loading ...
Support Center